NEWS
GE HEALTHCARE BRINGS ADVANCED DEEP LEARNING IMAGE RECONSTRUCTION TO CLINICIANS WORLDWIDE
GE HealthCare has unveiled three new advanced Deep Learning ( DL ) image processing and reconstruction solutions as a part of its Effortless Recon DL portfolio at the Radiological Society of North America ( RSNA ) 2024 Annual Meeting , in Chicago , IL . Understanding the need to improve operational efficiencies within radiology departments and the ongoing challenge of burnout experienced by clinicians , GE HealthCare developed the technologies to deliver exceptional image quality , reduce scan times and support improved patient outcomes .
The quality of clinical images plays a crucial role in providing accurate diagnoses and optimising patient care . As technology continues to evolve – Deep Learning – a subset of Artificial Intelligence ( AI ), has emerged as a powerful tool for clinicians . It can positively impact diagnostic accuracy and improve disease detection , which can help improve patient outcomes across clinical specialties .
“ Blurry images can compromise clinicians ’ ability to diagnose with confidence and speed ,” said Roland Rott , President and CEO , Imaging , GE HealthCare . “ At GE HealthCare , we ’ re ushering in a new era of image resolution with Deep Learning-powered imaging reconstruction . These AI-powered solutions not only enhance image quality but also streamline workflows , enabling radiologists to work more efficiently and cost-effectively . It also has the potential to provide patients ’ more timely access to imaging and consequentially may enable earlier diagnosis and treatment . By leveraging AI and Deep Learning technologies , we remain committed to delivering advancements that help empower clinicians to make more confident diagnoses and improve outcomes for patients worldwide .”
£ 72MN BOOST FOR COMMERCIAL RESEARCH TO BENEFIT THE HEALTH OF ENGLAND
The NIHR is announcing £ 72 million of funding to establish 14 new Commercial Research Delivery Centres ( CRDCs ) across England .
The new centres will enhance the speed and efficiency of commercial clinical research delivery , contributing to the health and wealth of the nation . They will work with industry and other research delivery infrastructure to support the UK ’ s status as one of the best places in the world for innovative companies to bring their portfolio of research .
The CRDCs will :
• build further capacity in commercial contract research
• provide dedicated staff and facilities to conduct commercial research
• provide access to a network of commercially active sites with gold-standard set-up times and performance
• make taking part in research as easy as possible , by supporting the decentralisation of clinical trials to smaller district general hospitals and primary care settings
• increase research inclusion to ensure people from all eligible communities , including those living with the greatest burden of disease , can participate in clinical trials
• support and contribute to a newly convened UK-wide CRDC Network , working as a collaborative partner across the NIHR and equivalent organisations in the devolved nations
A UK-wide scheme
This £ 72 million investment over 7 years , beginning in April 2025 , is awarded from the £ 400 million Voluntary Scheme for Branded Medicine Pricing , Access , and Growth ( VPAG ) Investment Programme and partly from NIHR in England .
The VPAG programme is a unique partnership between the UK Government and the pharmaceutical industry to boost the global competitiveness of the UK life sciences sector and stimulate economic growth .
It will invest up to £ 300 million to bolster commercial clinical trial activity and help advance the delivery of new medicines and vaccines to patients .
www . intelligenthealth . tech 7